The deal is modestly sized for Labcorp (market cap ~$50B) and appears strategically bolt-on, expanding specialty testing and geographic reach. Watch for regulatory clearance timeline and any integration cost guidance on the next earnings call. The 4Kscore earnout provides upside optionality if adoption accelerates.
Price Chart
Executive Summary
Labcorp agreed to acquire select assets of BioReference Health from OPKO Health for $722M in cash at closing, plus up to $150M in earnout based on 4Kscore Test revenue. The deal expands Labcorp's specialty testing menu (clinical, women's health, urology, corrections) and adds over 80 patient service centers. Expected first-year revenue from the acquired business is ~$250M, implying a ~3x revenue multiple on the base purchase price, which appears accretive.
Key Financial Metrics
Key Facts
- Purchase price: $722M in cash at closing, subject to working capital adjustment, plus up to $150M earnout based on 4Kscore Test revenue.
- Acquired assets include BioReference Health's clinical and women's health testing, urology, corrections testing, over 80 patient service centers, and the FDA-approved 4Kscore Test.
- Labcorp expects first-year post-close revenue from the acquired business to be approximately $250M.
- Transaction is subject to regulatory approvals and customary closing conditions; no operational changes until close.
- Labcorp's Diagnostics President Bryan Vaughn cited expanded access and specialty testing capabilities as strategic rationale.
Financial Impact
$722M base cash purchase price plus up to $150M earnout; expected first-year revenue ~$250M; implied base multiple ~2.9x revenue.
Risk Factors
- Regulatory approval risk — transaction requires customary antitrust and other regulatory clearances.
- Integration risk — combining BioReference's operations and patient service centers may cause near-term disruption.
- Earnout dependent on 4Kscore Test revenue — if adoption disappoints, the $150M earnout may not materialize.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302909289 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | Institutional Cluster | $329.90 | awaiting T+5 | — | $331.17 (+0.38%) |
Oct 21, 2026 6d ago | 8-K | $323.75 | awaiting T+5 | — | $331.17 (+2.29%) |
Oct 21, 2026 6d ago | Press Release | $323.75 | awaiting T+5 | — | $331.17 (+2.29%) |
Oct 20, 2026 8d ago | Court Ruling | $323.75 | awaiting T+5 | — | $331.17 (+2.29%) |
Oct 15, 2026 12d ago | Press Release | $325.07 $329.93 | ▲ +1.50% | ▲ +2.51% | $331.17 (+1.88%) |
Sep 30, 2026 27d ago | 8-K | $308.11 $311.97 | ▲ +1.25% | ▼ −0.66% | $331.17 (+7.48%) |
Sep 10, 2026 6w ago | 8-K | $311.54 $320.71 | ▲ +2.94% | ▲ +3.16% | $331.17 (+6.30%) |
Aug 28, 2026 8w ago | 8-K | $335.11 $326.89 | ▼ −2.45% | ▼ −2.56% | $331.17 (−1.18%) |
Aug 18, 2026 10w ago | Insider Cluster | $322.18 $337.68 | ▲ +4.81% | ▲ +5.01% | $331.17 (+2.79%) |
Aug 17, 2026 10w ago | 8-K | $323.34 $339.34 | ▲ +4.95% | ▲ +6.14% | $331.17 (+2.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers